News that a marketing authorisation application for two of its drugs had been accepted by the European Medicines Agency sent shares in GSK to a two-month high.
The FTSE 100 group said the agency had validated the application for its respiratory syncytial virus vaccine, as well as its injectable medicine to prevent HIV, a drug made by ViiV Healthcare, a joint venture majority-owned by GSK and also backed by Pfizer and Shionogi, of Japan.
The approvals come months after the former GlaxoSmithKline reported that the adult trial for respiratory syncytial virus showed 94.1 per cent reduction in severe RSV disease, a leading cause of pneumonia in toddlers and the elderly, and overall vaccine efficacy of 82.6 per cent. GSK reckons a European regulatory decision will
© Times Newspapers Limited 2022.
Registered in England No. 894646. Registered office: 1 London Bridge Street, SE1 9GF.